1
|
Salehi F, Hosseini-Zare MS, Aghajani H, Seyedi SY, Hosseini-Zare MS, Sharifzadeh M. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain. Fundam Clin Pharmacol 2017; 31:411-419. [PMID: 28267871 DOI: 10.1111/fcp.12282] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Revised: 01/26/2017] [Accepted: 03/02/2017] [Indexed: 11/30/2022]
Abstract
The aim of this study was to determine the effects of cyclic adenosine monophosphate (cAMP) and its dependent pathway on thermal nociception in a mouse model of acute pain. Here, we studied the effect of H-89 (protein kinase A inhibitor), bucladesine (Db-cAMP) (membrane-permeable analog of cAMP), and pentoxifylline (PTX; nonspecific phosphodiesterase (PDE) inhibitor) on pain sensation. Different doses of H-89 (0.05, 0.1, and 0.5 mg/100 g), PTX (5, 10, and 20 mg/100 g), and Db-cAMP (50, 100, and 300 nm/mouse) were administered intraperitoneally (I.p.) 15 min before a tail-flick test. In combination groups, we injected the first and the second compounds 30 and 15 min before the tail-flick test, respectively. I.p. administration of H-89 and PTX significantly decreased the thermal-induced pain sensation in their low applied doses. Db-cAMP, however, decreased the pain sensation in a dose-dependent manner. The highest applied dose of H-89 (0.5 mg/100 g) attenuated the antinociceptive effect of Db-cAMP in doses of 50 and 100 nm/mouse. Surprisingly, Db-cAMP decreased the antinociceptive effect of the lowest dose of H-89 (0.05 mg/100 g). All applied doses of PTX reduced the effect of 0.05 mg/100 g H-89 on pain sensation; however, the highest dose of H-89 compromised the antinociceptive effect of 20 mg/100 g dose of PTX. Co-administration of Db-cAMP and PTX increased the antinociceptive effect of each compound on thermal-induced pain. In conclusion, PTX, H-89, and Db-cAMP affect the thermal-induced pain by probably interacting with intracellular cAMP and cGMP signaling pathways and cyclic nucleotide-dependent protein kinases.
Collapse
Affiliation(s)
- Forouz Salehi
- Department of Pharmacology and Toxicology, Pharmaceutical Science Research Center, Tehran University of Medical Science, PO Box 14155-6451, Tehran, Iran
| | - Mahshid S Hosseini-Zare
- Department of Pharmacology and Toxicology, Pharmaceutical Science Research Center, Tehran University of Medical Science, PO Box 14155-6451, Tehran, Iran.,Department of Biology and Biochemistry, University of Houston, Houston, TX, 77204, USA
| | - Haleh Aghajani
- Department of Biomedical Engineering, University of Houston, Houston, TX, 77204, USA
| | - Seyedeh Yalda Seyedi
- Department of Pharmacology and Toxicology, Pharmaceutical Science Research Center, Tehran University of Medical Science, PO Box 14155-6451, Tehran, Iran
| | | | - Mohammad Sharifzadeh
- Department of Pharmacology and Toxicology, Pharmaceutical Science Research Center, Tehran University of Medical Science, PO Box 14155-6451, Tehran, Iran
| |
Collapse
|
2
|
Protective Effect of a cAMP Analogue on Behavioral Deficits and Neuropathological Changes in Cuprizone Model of Demyelination. Mol Neurobiol 2014; 52:130-41. [PMID: 25128030 DOI: 10.1007/s12035-014-8857-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2014] [Accepted: 08/06/2014] [Indexed: 01/06/2023]
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease that leads to neuronal cell loss. Cyclic AMP and its analogs are well known to decrease inflammation and apoptosis. In the present study, we examined the effects of bucladesine, a cell-permeable analogue of cyclic adenosine monophosphate (cAMP), on myelin proteins (PLP, PMP-22), inflammation, and apoptotic, as well as anti-apoptotic factors in cuprizone model of demyelination. C57BL/6J mice were fed with chow containing 0.2% copper chelator cuprizone or vehicle by daily oral gavage for 5 weeks to induce reversible demyelination predominantly of the corpus callosum. Bucladesine was administered intraperitoneally at different doses (0.24, 0.48, or 0.7 μg/kg body weight) during the last 7 days of 5-week cuprizone treatment. Bucladesine exhibited a protective effect on myelination. Furthermore, bucladesine significantly decreased the production of interleukin-6 pro-inflammatory mediator as well as nuclear factor-κB activation and reduced the mean number of apoptotic cells compared to cuprizone-treated mice. Bucladesine also decreased production of caspase-3 as well as Bax and increased Bcl-2 levels. Our data revealed that enhancement of intracellular cAMP prevents demyelination and plays anti-inflammatory and anti-apoptotic properties in mice cuprizone model of demyelination. This suggests the modulation of intracellular cAMP as a potential target for treatment of MS.
Collapse
|
3
|
Seyedi SY, Salehi F, Payandemehr B, Hossein S, Hosseini-Zare MS, Nassireslami E, Yazdi BB, Sharifzadeh M. Dual effect of cAMP agonist on ameliorative function of PKA inhibitor in morphine-dependent mice. Fundam Clin Pharmacol 2013; 28:445-54. [PMID: 24033391 DOI: 10.1111/fcp.12045] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2013] [Revised: 06/24/2013] [Accepted: 07/08/2013] [Indexed: 12/15/2022]
Abstract
The present study shows interactive effects of bucladesine (db-cAMP) as a cyclic adenosine monophosphate (cAMP) agonist and H-89 as a protein kinase A (PKA) inhibitor on naloxone-induced withdrawal signs in morphine-dependent mice. Animals were treated subcutaneously with morphine thrice daily with doses progressively increased from 50 to 125 mg/kg. A last dose of morphine (50 mg/kg) was administered on the 4th day. Several withdrawal signs were precipitated by intraperitoneal (i.p.) administration of naloxone (5 mg/kg). Different doses of bucladesine (50, 100, 200 nm/mouse) and H-89 (0.05, 0.5, 1, 5 mg/kg) were administered (i.p.) 60 min before naloxone injection. In combination groups, bucladesine was injected 15 min before H-89 injection. Single administration of H-89 (0.5, 1, 5 mg/kg) and bucladesine (50, 100 nm/mouse) significantly attenuated prominent behavioral signs of morphine withdrawal. Lower doses of bucladesine (50, 100 nm/mouse) in combination with H-89 (0.05 mg/kg) increased the inhibitory effects of H-89 on withdrawal signs while in high dose (200 nm/mouse) decreased the ameliorative function of H-89 (0.05 mg/kg) in morphine-dependent animals. It is concluded that H-89 and bucladesine could affect morphine withdrawal syndrome via possible interaction with cyclic nucleotide messengering systems, protein kinase A signaling pathways, and modified related neurotransmitters.
Collapse
Affiliation(s)
- Seyedeh Y Seyedi
- Department of Pharmacology and Toxicology, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, PO Box 14155-6451, Tehran, Iran
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Mehrotra A, Shanbhag R, Chamallamudi MR, Singh VP, Mudgal J. Ameliorative effect of caffeic acid against inflammatory pain in rodents. Eur J Pharmacol 2011; 666:80-6. [DOI: 10.1016/j.ejphar.2011.05.039] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2010] [Revised: 05/16/2011] [Accepted: 05/22/2011] [Indexed: 01/10/2023]
|
5
|
Wang XM, Hamza M, Gordon SM, Wahl SM, Dionne RA. COX Inhibitors Downregulate PDE4D Expression in a Clinical Model of Inflammatory Pain. Clin Pharmacol Ther 2008; 84:39-42. [DOI: 10.1038/sj.clpt.6100501] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
6
|
Vale ML, Benevides VM, Sachs D, Brito GAC, da Rocha FAC, Poole S, Ferreira SH, Cunha FQ, Ribeiro RA. Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br J Pharmacol 2004; 143:833-44. [PMID: 15520047 PMCID: PMC1575939 DOI: 10.1038/sj.bjp.0705999] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The antihyperalgesic effect of pentoxifylline was investigated in three experimental pain models. Pentoxifylline (0.5-1.6 mg kg(-1)) given 30 min before the stimulus significantly inhibited the writhing response induced by the intraperitoneal (i.p.) administration of either acetic acid (-90%) or zymosan (-83%), but not that of iloprost, in mice, as well as the zymosan-induced articular hyperalgesia in the zymosan arthritis in rats (-50%). Pentoxifylline also inhibited the mechanical hypernociception in rats induced by the intraplantar injection of either carrageenin (-81%), bradykinin (-56%) or tumor necrosis factor alpha (TNF-alpha; -46%), but not that induced by interleukin-1beta (IL-1beta) or prostaglandin E(2) (PGE(2)). Pentoxifylline did not inhibit the nociceptive response in the hot plate test in mice. Further, the antinociceptive effect of pentoxifylline in the writhing test in mice and the zymosan-induced articular hyperalgesia were not reversed by the coadministration of the opioid receptor antagonist naloxone. Thus, pentoxifylline antinociceptive effect is probably not mediated at a central level. Pentoxifylline significantly reduced TNF-alpha (-43%) and IL-1beta (-42%) concentrations in the joint exudates of rats stimulated by intra-articular injection of zymosan and the production of both cytokines (-66 and -86%, respectively) by mouse peritoneal macrophages stimulated in vivo with zymosan as well as the expression of TNF-alpha at the tissue level in carrageenin-injected rat paws. In conclusion, the antinociceptive activity of pentoxifylline is associated with the inhibition of the release of both TNF-alpha and IL-1beta.
Collapse
Affiliation(s)
- Mariana L Vale
- Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Rua Cel, Nunes de Melo, 1127, CEP 60430-270, Fortaleza, CE, Brazil
| | - Verônica M Benevides
- Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Rua Cel, Nunes de Melo, 1127, CEP 60430-270, Fortaleza, CE, Brazil
| | - Daniela Sachs
- Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, SP, Brazil
| | - Gerly A C Brito
- Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Rua Cel, Nunes de Melo, 1127, CEP 60430-270, Fortaleza, CE, Brazil
| | - Francisco A C da Rocha
- Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Rua Cel, Nunes de Melo, 1127, CEP 60430-270, Fortaleza, CE, Brazil
| | - Stephen Poole
- Endocrinology Section, National Institute for Biological Standards and Control (NIBSC), London
| | - Sérgio H Ferreira
- Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, SP, Brazil
| | - Fernando Q Cunha
- Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, SP, Brazil
| | - Ronaldo A Ribeiro
- Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Rua Cel, Nunes de Melo, 1127, CEP 60430-270, Fortaleza, CE, Brazil
- Author for correspondence:
| |
Collapse
|
7
|
Viana CFG, Melo DH, Carneiro-Filho BA, Michelin MA, Brito GAC, Cunha FQ, Lima AAM, Ribeiro RA. Pro-inflammatory effects of cholera toxin: role of tumor necrosis factor alpha. Toxicon 2002; 40:1487-94. [PMID: 12368119 DOI: 10.1016/s0041-0101(02)00170-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Cholera toxin has been traditionally described as the one that does not induce inflammation. It has, however, potent adjuvant and immuno-modulatory activities. Since the adjuvanticity of other compounds is linked to their capacity to induce inflammation, in the present study the pro-inflammatory activity of cholera toxin was investigated. We studied this activity in the following rat models of inflammation: paw edema and neutrophil migration into the peritoneal cavity, and evaluated cholera toxin's effect on tumor necrosis factor alpha (TNF-alpha) production by mouse macrophages. We, also, explored the effects of dexamethasone (DEXA) and of two inhibitors of TNF-alpha production, thalidomide (TAL) and pentoxifylline, on paw swelling. Cholera toxin-induced significant and dose-dependent paw edema, which peaked 48 h after toxin challenge (Cholera toxin(2.5 microg): 2.39 +/- 0.22 ml). Cholera toxin B subunit did not show edematogenic activity. DEXA, TAL and pentoxifylline significantly reduced cholera toxin-induced edema (DEXA(0.5 mg/kg): 42.6% of inhibition; TAL(45 mg/kg): 36% of inhibition; pentoxifylline (45 mg/kg): 61% of inhibition). Neither cholera toxin nor its B subunit induced neutrophil migration into peritoneal cavities. Cholera toxin stimulated the release of TNF-alpha by macrophages (cholera toxin(10 microg): 11.46 +/- 0.44 UI/ml). These data provide evidences that cholera toxin exhibits significant pro-inflammatory activity. It also indicates the role of TNF-alpha upon the pathophysiology of this event based on the inhibitory action of DEXA, TAL and pentoxifylline, and on TNF-alpha secretion induced by cholera toxin.
Collapse
Affiliation(s)
- C F G Viana
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará-UFC, Rua Cel Nunes de Melo 1127, 60430-270 Fortaleza, Ceará, Brazil
| | | | | | | | | | | | | | | |
Collapse
|